Year |
Citation |
Score |
2023 |
Gallagher CI, Frangos ZJ, Sheipouri D, Shimmon S, Duman MN, Jayakumar S, Cioffi CL, Rawling T, Vandenberg RJ. Novel Phenylene Lipids That Are Positive Allosteric Modulators of Glycine Receptors and Inhibitors of Glycine Transporter 2. Acs Chemical Neuroscience. PMID 37466545 DOI: 10.1021/acschemneuro.3c00167 |
0.333 |
|
2022 |
York E, McNaughton DA, Roseblade A, Cranfield CG, Gale PA, Rawling T. Structure-Activity Relationship and Mechanistic Studies of Bisaryl Urea Anticancer Agents Indicate Mitochondrial Uncoupling by a Fatty Acid-Activated Mechanism. Acs Chemical Biology. PMID 35854216 DOI: 10.1021/acschembio.1c00807 |
0.311 |
|
2020 |
Roy R, Roseblade A, Rawling T. Expansion of the structure-activity relationship of branched chain fatty acids: effect of unsaturation and branching group size on anticancer activity. Chemistry and Physics of Lipids. 104952. PMID 32814085 DOI: 10.1016/J.Chemphyslip.2020.104952 |
0.352 |
|
2020 |
Gallagher CI, Sheipouri D, Shimmon S, Rawling T, Vandenberg RJ. Identification of N-acyl amino acids that are positive allosteric modulators of glycine receptors. Biochemical Pharmacology. 114117. PMID 32579961 DOI: 10.1016/J.Bcp.2020.114117 |
0.368 |
|
2020 |
Mostyn SN, Sarker S, Muthuraman P, Raja A, Shimmon S, Rawling T, Cioffi CL, Vandenberg RJ. A photoswitchable ORG25543 congener enables optical control of glycine transporter 2. Acs Chemical Neuroscience. PMID 32191428 DOI: 10.1021/Acschemneuro.9B00655 |
0.623 |
|
2020 |
Rawling T, MacDermott-Opeskin H, Roseblade A, Pazderka C, Clarke C, Bourget K, Wu X, Lewis W, Noble B, Gale PA, O'Mara ML, Cranfield C, Murray M. Aryl urea substituted fatty acids: a new class of protonophoric mitochondrial uncoupler that utilises a synthetic anion transporter Chemical Science. DOI: 10.1039/D0Sc02777D |
0.335 |
|
2019 |
Murray M, Roseblade A, Chen Y, Bourget K, Rawling T. Carbon chain length modulates MDA-MB-231 breast cancer cell killing mechanisms by mitochondrially targeted aryl-urea fatty acids. Chemmedchem. PMID 31773850 DOI: 10.1002/Cmdc.201900577 |
0.36 |
|
2019 |
Murray M, Gillani TB, Rawling T, Nair PC. Inhibition of Hepatic CYP2D6 by the Active N-Oxide Metabolite of Sorafenib. The Aaps Journal. 21: 107. PMID 31637538 DOI: 10.1208/S12248-019-0374-2 |
0.375 |
|
2019 |
Mostyn SN, Wilson KA, Schumann-Gillett A, Frangos ZJ, Shimmon S, Rawling T, Ryan RM, O'Mara ML, Vandenberg RJ. Identification of an allosteric binding site on the human glycine transporter, GlyT2, for bioactive lipid analgesics. Elife. 8. PMID 31621581 DOI: 10.7554/Elife.47150 |
0.38 |
|
2019 |
Mostyn SN, Rawling T, Mohammadi S, Shimmon S, Frangos ZJ, Sarker S, Yousuf A, Vetter I, Ryan RM, Christie MJ, Vandenberg RJ. Development of an N-acyl amino acid that selectively inhibits the glycine transporter 2 to produce analgesia in a rat model of chronic pain. Journal of Medicinal Chemistry. PMID 30714733 DOI: 10.1021/Acs.Jmedchem.8B01775 |
0.643 |
|
2019 |
Ghassabian S, Gillani TB, Rawling T, Crettol S, Nair PC, Murray M. Sorafenib N-Oxide Is an Inhibitor of Human Hepatic CYP3A4. The Aaps Journal. 21: 15. PMID 30627802 DOI: 10.1208/S12248-018-0262-1 |
0.348 |
|
2019 |
Rahman K, Rawling T, Al-Zubaidi Y, Choucair H, Umashankar B, Chen Y, Bourget K, Tam S, Smith C, Murray M. Abstract A119: Inhibition of IRE1-mediated pro-tumorigenic responses enhances the sensitivity of MDA-MB-231 cells to the novel arylurea-fatty acid CTU Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A119 |
0.365 |
|
2018 |
Al-Zubaidi Y, Pazderka C, Koolaji N, Rahman MK, Choucair H, Umashankar B, Bourget K, Chen Y, Rawling T, Murray M. Aryl-urea fatty acids that activate the p38 MAP kinase and down-regulate multiple cyclins decrease the viability of MDA-MB-231 breast cancer cells. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. PMID 30597206 DOI: 10.1016/J.Ejps.2018.12.015 |
0.384 |
|
2018 |
Garrastazu Pereira G, Rawling T, Pozzoli M, Pazderka C, Chen Y, Dunstan CR, Murray M, Sonvico F. Nanoemulsion-Enabled Oral Delivery of Novel Anticancer ω-3 Fatty Acid Derivatives. Nanomaterials (Basel, Switzerland). 8. PMID 30322115 DOI: 10.3390/Nano8100825 |
0.347 |
|
2018 |
Pazderka CW, Oliver B, Murray M, Rawling T. Omega-3 Polyunsaturated Fatty Acid Derived Lipid Mediators and Their Application in Drug Discovery. Current Medicinal Chemistry. PMID 30259807 DOI: 10.2174/0929867325666180927100120 |
0.327 |
|
2018 |
Koolaji N, Rawling T, Bourget K, Murray M. Carboxylate analogues of aryl-urea-substituted fatty acids that target the mitochondrion in MDA-MB-231 breast cancer cells to promote cell death. Chemmedchem. PMID 29603659 DOI: 10.1002/Cmdc.201800018 |
0.39 |
|
2018 |
Winters BL, Rawling T, Vandenberg RJ, Christie MJ, Bhola RF, Imlach WL. Activity of novel lipid glycine transporter inhibitors on synaptic signalling in the dorsal horn of the spinal cord. British Journal of Pharmacology. PMID 29500820 DOI: 10.1111/Bph.14189 |
0.366 |
|
2017 |
Rawling T, Choucair H, Koolaji N, Bourget K, Allison SE, Chen YJ, Dunstan CR, Murray M. A novel aryl-urea fatty acid that targets the mitochondrion and depletes cardiolipin to promote killing of breast cancer cells. Journal of Medicinal Chemistry. PMID 28921987 DOI: 10.1021/Acs.Jmedchem.7B00701 |
0.364 |
|
2017 |
Dyari HRE, Rawling T, Chen Y, Sudarmana W, Bourget K, Dwyer JM, Allison SE, Murray M. A novel synthetic analogue of ω-3 17,18-epoxy-eicosatetraenoic acid activates TNF receptor-1/ASK1/JNK signaling to promote apoptosis in human breast cancer cells. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 28798154 DOI: 10.1096/Fj.201700033R |
0.33 |
|
2017 |
Mostyn SN, Carland JE, Shimmon S, Ryan RM, Rawling T, Vandenberg RJ. Synthesis and Characterization of Novel Acyl-Glycine Inhibitors of GlyT2. Acs Chemical Neuroscience. PMID 28574249 DOI: 10.1021/Acschemneuro.7B00105 |
0.42 |
|
2017 |
Murray M, Choucair H, Allison S, Bourget K, Chen Y, Dunstan C, Rawling T. O25 A novel synthetic ω-3 fatty acid epoxide analogue activates breast cancer cell killing in vitro and in vivo Biochemical Pharmacology. 139: 117. DOI: 10.1016/J.Bcp.2017.06.090 |
0.364 |
|
2015 |
Murray M, Hraiki A, Bebawy M, Pazderka C, Rawling T. Anti-tumor activities of lipids and lipid analogues and their development as potential anticancer drugs. Pharmacology & Therapeutics. 150: 109-28. PMID 25603423 DOI: 10.1016/J.Pharmthera.2015.01.008 |
0.367 |
|
2014 |
Gillani TB, Rawling T, Murray M. Cytochrome P450-Mediated Biotransformation of Sorafenib and Its N-Oxide Metabolite: Implications for Cell Viability and Human Toxicity. Chemical Research in Toxicology. PMID 25489883 DOI: 10.1021/Tx500373G |
0.315 |
|
2014 |
Johnston RA, Rawling T, Chan T, Zhou F, Murray M. Selective inhibition of human solute carrier transporters by multikinase inhibitors. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 1851-7. PMID 25165131 DOI: 10.1124/Dmd.114.059097 |
0.361 |
|
2014 |
Dyari HR, Rawling T, Bourget K, Murray M. Synthetic ω-3 epoxyfatty acids as antiproliferative and pro-apoptotic agents in human breast cancer cells. Journal of Medicinal Chemistry. 57: 7459-64. PMID 25144895 DOI: 10.1021/Jm501083Y |
0.378 |
|
2014 |
Murray M, Dyari HR, Allison SE, Rawling T. Lipid analogues as potential drugs for the regulation of mitochondrial cell death. British Journal of Pharmacology. 171: 2051-66. PMID 24111728 DOI: 10.1111/Bph.12417 |
0.324 |
|
2013 |
Cui PH, Rawling T, Gillani TB, Bourget K, Wang XS, Zhou F, Murray M. Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells. Biochemical Pharmacology. 86: 419-27. PMID 23732299 DOI: 10.1016/J.Bcp.2013.05.014 |
0.363 |
|
2012 |
Cui PH, Rawling T, Bourget K, Kim T, Duke CC, Doddareddy MR, Hibbs DE, Zhou F, Tattam BN, Petrovic N, Murray M. Antiproliferative and antimigratory actions of synthetic long chain n-3 monounsaturated fatty acids in breast cancer cells that overexpress cyclooxygenase-2. Journal of Medicinal Chemistry. 55: 7163-72. PMID 22822908 DOI: 10.1021/Jm300673Z |
0.366 |
|
2012 |
Ghassabian S, Rawling T, Zhou F, Doddareddy MR, Tattam BN, Hibbs DE, Edwards RJ, Cui PH, Murray M. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. Biochemical Pharmacology. 84: 215-23. PMID 22513143 DOI: 10.1016/J.Bcp.2012.04.001 |
0.355 |
|
2012 |
Doddareddy MR, Rawling T, Ammit AJ. Targeting mitogen-activated protein kinase phosphatase-1 (MKP-1): structure-based design of MKP-1 inhibitors and upregulators. Current Medicinal Chemistry. 19: 163-73. PMID 22320295 DOI: 10.2174/092986712803414196 |
0.335 |
|
2010 |
Rawling T, Duke CC, Cui PH, Murray M. Facile and stereoselective synthesis of (Z)-15-octadecenoic acid and (Z)-16-nonadecenoic acid: monounsaturated omega-3 fatty acids. Lipids. 45: 159-65. PMID 20069386 DOI: 10.1007/S11745-009-3378-3 |
0.306 |
|
Show low-probability matches. |